SEARCH

SEARCH BY CITATION

References

  • 1
    Goldhirsch A,Glick JH,Gelber RD,Coates AS,Thurlimann B,Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 156983.
  • 2
    Slamon DJ,Leyland-Jones B,Shak S,Fuchs H,Paton V,Bajamonde A,Fleming T,Eiermann W,Wolter J,Pegram M,Baselga J,Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 78392.
  • 3
    Arpino G,Weiss H,Lee AV,Schiff R,De Placido S,Osborne CK,Elledge RM. Estrogen receptor-positive, progesterone receptor-negativebreast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 125461.
  • 4
    Piccart-Gebhart MJ,Procter M,Leyland-Jones B,Goldhirsch A,Untch M,Smith I,Gianni L,Baselga J,Bell R,Jackisch C,Cameron D,Dowsett M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 165972.
  • 5
    Romond EH,Perez EA,Bryant J,Suman VJ,Geyer C,Davidson NE,Tan-Chiu E,Martino S,Paik S,Kaufman PA,Swain SM,Pisansky T et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 167384.
  • 6
    Ellis IO,Bartlett J,Dowsett M,Humphreys S,Jasani B,Miller K,Pinder SE,Rodes A,Walker R. Updated recommendations for HER2 testing in the UK. J Clin Pathol 2004; 57: 2337.
  • 7
    Paik S,Bryant J,Tan-Chiu E,Romond E,Hiller W,Park K,Brown A,Yothers G,Anderson S,Smith R,Wickerham DL,Wolmark N. Real-world performance of HER2 testing national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002; 94: 8524.
  • 8
    Roche PC,Suman VJ,Jenkins RB,Davidson NE,Martino S,Kaufman PA,Addo FK,Murphy B,Ingle JN,Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 8557.
  • 9
    Vincent-Salomon A,Jouve M,Genin P,Freneaux P,Sigal-Zafrani B,Caly M,Beuzeboc P,Pouillart P,Sastre-Garau X. Her2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002; 94: 216973.
  • 10
    Masood S,Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000; 30: 25965.
  • 11
    Niehans GA,Singleton TP,Dykoski D,Kiang DT. Stability of Her-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 12305.
  • 12
    Simon R,Nocito A,Hubscher T,Bucher C,Torhorst J,Schraml P,Bubendorf L,Mihatsch MM,Moch H,Wilber K,Schotzau A,Kononen J et al. Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 11416.
  • 13
    Shimizu C,Fukutomi T,Tsuda H,Akashi-Tanaka S,Watanabe T,Nanasawa T,Sugihara K. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 2000; 73: 1720.
  • 14
    Cardoso F,Di Leo A,Larsimont D,Gancberg D,Rouas G,Dolci S,Ferriera F,Paesmans M,Piccart M. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol 2001; 12: 61520.
  • 15
    Gong Y,Booser DJ,Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 17639.
  • 16
    Edgerton SM,Moore D,II,Merkel D,Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003; 11: 21421.
  • 17
    Gancberg D,Di Leo A,Cardoso F,Rouas G,Pedrocchi M,Paesmans M,Verhest A,Bernard-Marty C,Piccart MJ,Larsimont D. Comparison of Her-2 status between primary breast cancer andcorresponding distant metastatic sites. Ann Oncol 2002; 13: 103643.
  • 18
    Zidan J,Dashkovsky I,Stayerman C,Basher W,Cozacov C,Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 5526.
  • 19
    Kallioniemi OP,Kallioniemi A,Kurisu W,Thor A,Chen LC,Smith HS,Waldman FM,Pinkel D,Gray JW. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992; 89: 53215.
  • 20
    Thor AD,Berry DA,Budman DR,Muss HB,Kute T,Henderson IC,Barcos M,Cirrincione C,Edgerton S,Allred C,Norton L,Liu ET. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 134660.
  • 21
    Pertschuk LP,Axiotis CA,Feldman JG,Kim YD,Karavattayhayyil SJ,Braithwaite L. Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999; 5: 36974.
  • 22
    Santinelli A,Baccarini M,Colanzi P,Stramazzotti D,Fabris G. Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma. A study of reproducibility. Anal Quant Cytol Histol 2002; 24: 5462.
  • 23
    Pritchard KI,Shepherd LE,O'Malley FP,Andrulis IL,Tu D,Bramwell VH,Levin MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 18: 210311.
  • 24
    Regitnig P,Schippinger W,Lindbauer M,Samonigg H,Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004; 203: 91826.
  • 25
    Varga Z,Caduff R,Pestalozzi B. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005; 446: 13641.
  • 26
    Teixeira MR,Pandis N,Bardi G,Andersen JA,Mitelman F,Heim S. Clonal heterogeneity in breast cancer; karyotypic comparisons of multiple intra- and extra-tumorous samples from 3 patients. Int J Cancer 1995; 63: 638.
  • 27
    Kuukasjarvi T,Karhu R,Tanner M,Kahkonen M,Schaffer A,Nupponen N,Pennanen S,Kallioniemi A,Kallioniemi OP,Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997; 57: 15971604.
  • 28
    Slichenmeyer W,Fry D. Anticancer therapy targeting the Erb B family of receptor tyrosine kinases. Semin Oncol 2001; 28: 6779.
  • 29
    Tanner M,Jarvinen P,Isola J. Amplification of HER-2/neu and topoisomerase II-alfa in primary and metastatic breast cancer. Cancer Res 2001; 61: 53458.
  • 30
    Rasbridge SA,Gillett CE,Seymour AM,Patel K,Richards MA,Rubens RD,Millis RR. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994; 70: 33541.